Evaluation of Serum Adropin, Irisin, and Preptin Levels in Individuals with Benign Prostatic Hyperplasia and Prostate Cancer
Abstract
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are common urological conditions among aging men, characterized by benign enlargement and malignant progression of the prostate gland, respectively. This study was designed to answer the question of whether adropin, irisin, and preptin serum levels have an impact on the development of prostate disease in a total of 90 participants, including BPH (n=30), localized PCa (n=30), and healthy controls (n=30). The serum concentrations of these peptides were determined using enzyme-linked immunosorbent assay (ELISA). According to the findings, adropin and irisin levels were significantly lower in the BPH and PCa groups compared to the control group (p<0.001). Conversely, preptin levels were significantly higher in both the BPH and PCa groups compared to the control group (p<0.001), with preptin levels in the PCa group being higher than those in the BPH group (p<0.001). In conclusion, these findings highlight the complex interactions of these peptides in prostate pathophysiology, suggesting that adropin and irisin may be linked to metabolic dysregulation, while preptin is associated with cellular growth processes related to prostate malignancies. Furthermore, this study emphasizes the need for further studies to elucidate the specific roles and therapeutic potential of adropin, irisin and preptin in the management of prostate health and disease.
Keywords
Adropin, BPH, Irisin, Preptin, Prostate health
Ethical Statement
This study was approved by the Fırat University Non-Interventional Research Ethics Committee under protocol number 2023/08-35. All participants were informed about the study objectives and procedures before participation. Written informed consent was obtained from all participants prior to inclusion in the study.
References
- Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia—what do we know? BJU Int. 2021;127(4):389-399.
- Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Lausanne). 2021;12:554078.
- Kania E, Janica M, Nesterowicz M, Modzelewski W, Cybulski M, Janica J. Advances and challenges in prostate cancer diagnosis: a comprehensive review. Cancers (Basel). 2025;17(13):2137.
- Bergengren O, Pekala KR, Matsoukas K, et al. 2022 update on prostate cancer epidemiology and risk factors—a systematic review. Eur Urol. 2023;84(2):191-206.
- Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M. Adropin as a fat-burning hormone with multiple functions—review of a decade of research. Molecules. 2020;25(3):549.
- Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options. Int J Urol. 2024;31(9):968-974.
- Chen L, Lu J, Hu J, Gong X. Unveiling the multifaceted role of adropin in various diseases (review). Int J Mol Med. 2024;54(4):90.
- Ungureanu MC, Bilha SC, Hogas M, Velicescu C, Leustean L, Teodoriu LC, Preda C. Preptin: a new bone metabolic parameter? Metabolites. 2023;13(9):991.
- Mrázková L, Lubos M, Voldřich J, et al. The final walk with preptin. PLoS One. 2024;19(9):e0309726.
- Nwabo Kamdje AH, Seke Etet PF, Kipanyula MJ, et al. Insulin-like growth factor-1 signaling in the tumor microenvironment: carcinogenesis, cancer drug resistance, and therapeutic potential. Front Endocrinol (Lausanne). 2022;13:927390.